Keynote-057: Extended Follow-Up Of Pembrolizumab In Bladder Cancer

KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancer

KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Pembrolizumab shows notable anti-tumour activity for patients with high-risk NMIBC

Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBC

Management of BCG Unresponsive Cystectomy Ineligible Bladder Cancer Patients Pembrolizumab

Grand Rounds in Urology

Yair Lotan, MD, shares outcomes of KEYNOTE 057 in high-risk non-muscle-invasive bladder cancer

How effective is pembrolizumab in cisplatin-ineligible bladder cancer? Results from KEYNOTE-052

Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity

Pembrolizumab in Patients with Locally Advanced Bladder Cancer

Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

Activity of Immunotherapy in the Frontline Setting

ASCO GU 2019 - Dr. Arjun V Balar, NYU Langone's Pearlmutter Cancer Center, USA

Oncology Information Group

Pembrolizumab plus enfortumab vedotin for bladder cancer

KEYNOTE-992: pembrolizumab plus chemoRT for MIBC

Two-Year Follow-Up Results from KEYNOTE-045 Study in Urothelial Carcinoma

Targeted Oncology

Dr. Bellmunt Shares KEYNOTE-045 Data for Pembrolizumab Versus Chemotherapy in Bladder Cancer

AMBASSADOR: pembrolizumab for locally advanced bladder cancer

Examining the State of the Science on New Therapies in Bladder Cancer

PeerView Oncology

Understanding the Evolving Treatment Landscape in Bladder Cancer